I'm LongbridgeAI, I can summarize articles.Hong Kong small-caps are increasingly channeling capital into technology and biotech pivots, with strategic acquisitions serving as the primary catalyst. LQIDA Tech (9611.HK) finalized its 60% stake acquisition in Suzhou Anruike in late October, establishing a foothold in data center infrastructure while launching a robotics subsidiary for embodied AI data collection. LeadMind Pharma (2105.HK) reported positive 24-week trial results for its weight-loss drug LAE102, showing consistent muscle gain and fat reduction without severe adverse events.
Gotech Fiber (9963.HK) allocated CNY 250 million to acquire optical fiber preform assets, shifting its upstream business contribution from 8.85% to nearly 60% of total revenue. AiLife International (0784.HK) completed its rebranding under HaploX ownership to focus on genetic testing, while GenSea Medical (2225.HK) saw its minimally invasive surgical solutions grow to 74.73% of revenue, attracting sustained southbound capital inflows.
Traditional sectors show divergent trajectories. 361 Degrees (1361.HK) maintained its 8%-10% full-year revenue guidance amid robust Southeast Asian expansion, while ChipSMT (0365.HK) navigated SMT equipment headwinds through energy business stabilization. MicroPort Medical (0853.HK) remains suspended for over two months amid lease dispute investigations, with new management implementing governance reviews. Crayon Shin-chan Food (1262.HK) posted wider losses following Qucloud acquisition, as Yuehua Entertainment (2306.HK) explores AI-driven entertainment through VR music films.
